- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Reputation Institute Announces Annual Pharma RepTrak Ratings
Reputation Institute (RI), provider of reputation measurement, monitoring, and management services, announced its annual US Pharma RepTrak rankings. The survey looks at 2,608 individual ratings of pharma companies for the first quarter of 2018 and quantifies the emotional bond stakeholders have with pharma companies in the US, and how these connections drive supportive behavior such as the willingness to purchase a company’s products, recommend the brand, invest in or work for a company.
The top 10 companies in RI’s 2018 US Pharma RepTrak are:
1. Sanofi
2. Genentech
3. Celgene
4. AbbVie
5. Biogen
6. Bayer
7. Gilead
8. Allergan
9. Novo Nordisk
10. McKesson
The 2018 US Pharma RepTrak results reveal that national and industry reputations are under stress, with pharmaceutical companies following the broader national trends with a -3.7 point decline in reputation score compared to 2017. RI’s research analyst, Meghan Burke, wrote about this in detail for Pharm Exec’s blog. See her blog post here.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
